Evaluation of Selective 5-HT2C Agonists in Acute Seizure Models
- 13 May 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 10 (7) , 3284-3295
Abstract
The 5-HT releaser/reuptake inhibitor fenfluramine has been recently reported to provide benefit as an adjunctive treatment for Dravet and Lennox-Gastaut syndromes, two types of severe childhood epilepsy. Despite its enhancement of 5-HT function, many effects of fenfluramine have been demonstrated to be dependent on 5-HT2C receptor activation, suggesting that 5-HT2C receptor activation may have an anticonvulsant property. The present study was designed to evaluate fenfluramine and 5-HT agonists of varying 5-HT2C agonist selectivity, the relatively nonselective mCPP and Ro 60-0175, and the selective 5-HT2C agonists lorcaserin and CP-809101 across a variety of acute seizure tests conducted in adult rats and mice, which have been instrumental in identifying the majority of clinically efficacious antiepileptic drugs. Tests included the maximal electroshock seizure (MES), MES threshold, and 6 Hz electrical convulsive seizure models and the chemoconvulsant pentylenetetrazole test. The effect of mCPP, lorcaserin, and CP-809101 against electrically evoked seizures in amygdala kindled rats was also investigated. Overall, at doses known to interact with 5-HT2CR, there was no clear class-related effect of these agonists in any test. The only notable antiseizure effect of fenfluramine was inhibition of MES-induced tonic seizures in the rat. The current preclinical studies using the classical acute seizure tests and an amygdala kindling model do not identify a reliable antiseizure effect of fenfluramine, an agent now used in the treatment of human epilepsies, including Dravet syndrome and Lennox-Gastaut syndrome. Given the nature of these epilepsies, early life and/or genetic models may have better construct validity and be more appropriate for further study.Keywords
Funding Information
- Transpharmation Ltd
- InterVivo Solutions Inc
This publication has 72 references indexed in Scilit:
- Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical developmentEpilepsia, 2018
- Emerging drugs for the treatment of Dravet syndromeExpert Opinion on Emerging Drugs, 2018
- A pilot, open‐label study of the effectiveness and tolerability of low‐dose ZX008 (fenfluramine HCl) in Lennox‐Gastaut syndromeEpilepsia, 2018
- Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet SyndromeNew England Journal of Medicine, 2017
- Cannabinoids in treatment-resistant epilepsy: A reviewEpilepsy & Behavior, 2017
- Lennox–Gastaut Syndrome: A State of the Art ReviewNeuropediatrics, 2017
- Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndromeTherapeutic Advances in Neurological Disorders, 2015
- Successful use of fenfluramine as an add‐on treatment for Dravet syndromeEpilepsia, 2012
- Serotonin releasing agentsPharmacology Biochemistry and Behavior, 2002
- Behavioral evidence for the rapid release of CNS serotonin by PCA and fenfluramineEuropean Journal of Pharmacology, 1976